IP Library Granted Patent US 8,821,857
Granted Patent B2
US 8,821,857 · App. 13/212,661 · Granted Sep 2, 2014

Human placental collagen compositions and methods of making and using the same

Inventors: Mohit Bhatia (North Brunswick, NJ); Chris Lugo (Madison, NJ); Qian Ye (Livingston, NJ); James W. Edinger (Belford, NJ)
Assignee: Anthrogenesis Corporation
A61K38/39A61Q19/08A61K8/65A61Q19/00C07K14/78
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,821,857
App. No.
13/212,661
Granted
Sep 2, 2014
Kind
B2
Abstract

The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.

Claims (24)

1. A method of making a composition comprising telopeptide collagen, comprising, in order, the steps of:

(a) macerating placental tissue;

(b) suspending the placental tissue in a hypertonic saline solution;

(c) suspending the placental tissue in water; and

(d) treating the placental tissue with a mild detergent,

wherein said collagen has not been chemically modified or contacted with a base as part of the method, and wherein said composition additionally comprises 10% to about 12% elastin by dry weight, glycosaminoglycans, and less than 1% fibronectin or less than 1% laminin by weight after said method is completed.

2. The method of claim 1 , wherein the hypertonic saline solution comprises sodium chloride.

3. The method of claim 1 , further comprising the step of filtering the placental tissue.

4. The method of claim 1 , wherein said placental tissue is human placental tissue.

5. A method of making a composition comprising telopeptide collagen, comprising, in order, the steps of:

(a) macerating placental tissue;

(b) treating the placental tissue with a mild detergent, and

(c) treating the placental tissue with a base,

wherein said collagen has not been chemically modified as part of the method, and wherein said composition additionally comprises between 3% and 5% elastin by weight, glycosaminoglycans, and less than 0.01% laminin or less than 0.01% fibronectin by weight.

6. The method of claim 5 , wherein said base comprises ammonium hydroxide, potassium hydroxide, or sodium hydroxide.

7. The method of claim 5 , further comprising the step of filtering the placental tissue.

8. The method of claim 5 , wherein said placental tissue is human placental tissue.

9. The method of claim 1 , wherein said composition comprises between 74% and 92% Type I collagen by weight.

10. The method of claim 9 , wherein said composition further comprises 4% to 6% Type III collagen or 2% to 15% Type IV collagen by weight.

11. The method of claim 1 , wherein said detergent is deoxycholate.

12. The method of claim 5 , wherein said composition comprises between 74% and 92% Type I collagen by weight.

13. The method of claim 12 , wherein said composition further comprises 4% to 6% Type III collagen or 2% to 15% type IV collagen by weight.

14. The method of claim 5 , wherein said detergent is deoxycholate.

15. The method of claim 1 , wherein said composition comprises about 12% elastin.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2025
From: CELULARITY INC.
To: CELENIV PTE. LTD.
Reel/Frame 073705/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2018
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 045209/0509 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2012
From: BHATIA, MOHIT; LUGO, CHRIS; YE, QIAN; EDINGER, JAMES W.
To: ANTHROGENESIS CORPORATION
Reel/Frame 027832/0244 →
Continuity (3)
Continuation 11973902 · Oct 9, 2007
Provisional Application 60850131 · Oct 6, 2006
Related Publication 20110306755A1 · Dec 15, 2011